Business
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC\nCompleted enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025\nAnnounced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size\nEnded 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026\nManagement to host a conference call and webcast today at 4:30 p.m. ET \nNEW HAVEN, Conn., March 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter and year ended December 31, 2024, and provided business updates.\n\n \n \n \n \n \n \n\n \n\"Trevi had three positive and meaningful clinical data read-outs over the past few months validating the strategy of developing Haduvio as a potential best-in-class therapy for chronic cough conditions,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"With Haduvio, we are looking to address a significant unmet need across chronic cough conditions where there are no therapies approved in the U.S. Haduvio has the unique potential to work across various chronic cough conditions due to its central and peripheral mechanism. We look forward to our expected readout of topline results for the Phase 2b CORAL trial in IPF chronic cough patients in the second quarter of this year.\"\nFourth Quarter and Recent Business Highlights\nPositive topline data in the Phase 2a RIVER trial for the treatment of patients with RCC (N=66) in March 2025. Haduvio met the primary endpoint with a statistically-significant reduction (p","length":3872,"tagName":"div"}]